bronchiectasi
chronic
lung
diseas
cld
character
irrevers
bronchial
dilat
note
comput
tomographi
associ
chronic
cough
ongo
viscid
sputum
product
recurr
pulmonari
patient
classifi
two
group
cystic
fibrosi
cf
without
cf
individu
either
cfrelat
bronchiectasi
cfrb
noncfrel
bronchiectasi
ncfrb
experi
continu
airway
inflamm
lead
airway
chang
foster
develop
uniqu
polymicrobi
commun
chronic
pulmonari
infect
mani
organ
worsen
airway
inflamm
trigger
pulmonari
exacerb
pex
reduc
qualiti
life
qol
case
independ
risk
factor
increas
mortal
cure
either
condit
prevent
control
infect
paramount
infect
prevent
complex
undertak
aim
reduc
acquisit
patholog
organ
mitig
effect
patient
becom
infect
specif
incorpor
transmiss
prevent
immunoprophylaxi
occasion
antimicrobi
acquir
howev
organ
may
erad
erad
unsuccess
chronic
suppress
inflamm
organ
activ
becom
focu
therapi
topic
import
infect
control
prevent
beyond
scope
discuss
detail
regard
mechan
airway
clearanc
treatment
screen
nontubercul
mycobacteria
ntm
team
educ
sizabl
undertak
incorpor
rational
infect
prevent
method
microbi
transmiss
best
affect
chang
patient
famili
member
healthcar
team
includ
import
rememb
healthcar
team
limit
clinic
provid
includ
anyon
may
contact
patient
schedul
staff
phlebotomist
radiolog
technician
environment
servic
provid
clinic
hospit
ward
need
clinic
champion
task
organ
educ
plan
ensur
complianc
establish
protocol
teach
materi
present
tailor
recipi
educ
level
age
preexist
concept
regard
prevent
specif
role
team
patient
must
empow
ask
provid
follow
known
guidelin
team
member
need
educ
colleagu
laps
notic
regular
train
personnel
immedi
individu
feedback
follow
protocol
deviat
help
provid
effect
institut
protocol
improv
individu
clinic
practic
final
qualiti
feedback
strongli
relat
guidelin
adher
formal
review
process
outlin
team
success
area
need
improv
occur
everi
immunoprophylaxi
prevent
diseas
via
passiv
activ
unfortun
adult
children
global
discord
recommend
vaccin
schedul
addit
cfrb
mani
caus
ncfrb
lead
system
diseas
may
benefit
nonpulmonari
vaccin
thu
even
though
recommend
person
cld
receiv
pulmonari
vaccin
accord
nation
recommend
schedul
one
must
also
consid
nonpulmonari
organ
involv
determin
avail
vaccin
may
benefici
patient
cdc
multipl
suggest
regard
vaccin
person
foremostli
includ
annual
influenza
vaccin
recommend
person
month
age
older
unless
medic
contraind
exist
person
also
receiv
standard
treatment
chemoprophylaxi
oseltamivir
diagnos
expos
acut
influenza
contrast
healthi
person
cld
recommend
receiv
pneumococc
vaccin
begin
much
earlier
healthi
individu
age
instead
import
keep
uptod
pertussi
booster
cfrb
howev
practic
pattern
differ
sometim
differ
guidelin
see
liver
diseas
complic
clinic
cours
mani
patient
cfrb
ncfrb
one
could
consid
viral
hepat
vaccin
exampl
us
patient
cf
liver
pi
zz
antitrypsin
person
cf
experi
noncirrhot
cirrhot
liver
diseas
respect
children
cf
clinic
signific
liver
person
antitrypsin
defici
pi
zz
histolog
evid
signific
liver
diseas
frank
despit
inactiv
hepat
recombin
hepat
b
vaccin
shown
safe
effect
chronic
liver
diseas
pauciti
recommend
aim
captur
inadequ
histor
streptococcu
pneumonia
commonli
cultur
cf
specul
isol
underestim
due
domin
addit
recent
public
suggest
pediatr
carrier
state
high
nevertheless
littl
data
demonstr
invas
pneumococc
diseas
cf
thu
clinic
relev
pneumococc
vaccin
seem
hand
risk
pulmonari
invas
pneumococc
diseas
significantli
increas
follow
lung
thu
immunosuppress
blunt
immun
respons
pretranspl
pneumococc
vaccin
addit
longterm
impact
new
cf
transmembran
regul
protein
modul
ivacaftor
lumacaftorivacaftor
tezacaftorivacaftor
elexacaftortezacaftorivacaftor
current
develop
life
expect
pulmonari
microbiota
cfrb
unknown
prompt
caregiv
consid
whether
vaccin
may
indic
sourc
contain
wouldb
pathogen
compris
understand
organ
transmit
precaut
requir
diminish
spread
practic
address
bronchiectasi
interact
individu
acquir
new
flora
persontoperson
contact
contamin
medic
equip
via
multitud
ecolog
persontoperson
transmiss
may
occur
direct
contact
indirect
contact
droplet
transmiss
airborn
transmiss
dropletnuclei
tabl
patient
expel
infecti
particl
cough
sneez
speak
undergo
chest
physiotherapi
cpt
perform
pulmonari
function
test
pft
intub
organ
transmit
via
one
primari
mode
transmiss
may
occur
via
rout
pseudomona
aeruginosa
exampl
typic
acquir
water
sourc
reservoir
hot
tub
sink
shower
howev
surviv
longer
cf
sputum
may
transmit
via
handshak
min
follow
skin
isol
infecti
droplet
hospit
room
clinic
hallway
follow
pulmonari
function
test
min
infect
individu
addit
infecti
droplet
implic
vector
epidem
outbreak
occur
european
adult
cf
methicillin
resist
staphylococcu
aureu
mrsa
may
spread
via
contact
infecti
influenza
usual
transmit
via
fomit
droplet
suggest
airborn
isol
implement
pandem
addit
incorpor
recommend
decreas
crossinfect
outlin
cdc
mani
outpati
clinic
incorpor
cohort
segreg
ie
patient
burkholderia
spp
seen
one
day
p
aeruginosa
anoth
physic
separ
distanc
infect
control
sever
studi
report
reduct
rate
patientto
patient
transmiss
p
aeruginosa
burkholderia
spp
combin
cohort
segreg
intervent
equip
decontamin
patient
educ
use
barrier
littl
data
cohort
segreg
alon
ie
without
combin
infect
control
intervent
cf
foundat
support
physic
current
physic
separ
defin
approxim
recent
data
howev
suggest
infect
droplet
nuclei
may
travel
far
import
consider
clinic
patient
wait
line
lobbi
checkin
checkout
final
regardless
healthcar
set
patient
wear
mask
exam
hospit
healthcar
worker
hcw
need
practic
meticul
hand
hygien
use
appropri
person
protect
equip
ppe
clean
hand
contact
patient
use
waterless
antisept
cleanser
superior
antimicrobi
upon
exit
patient
room
isol
clostridium
difficil
hand
cleans
use
soap
water
prefer
alcoholbas
cleaner
disinfect
c
difficil
contact
patient
expel
airway
secret
gown
glove
relev
team
member
may
need
wear
mask
surgic
protect
eye
cover
intub
provid
must
clean
stethoscop
patient
use
patientspecif
pulmonari
function
test
pft
result
product
mani
aerosol
whether
patient
complet
basic
spirometri
complet
pulmonari
test
procedur
must
perform
neg
pressur
room
one
equip
high
effici
particul
air
hepa
filter
precaut
possibl
test
separ
method
clean
medic
equip
paramount
infect
control
airway
clearanc
devic
nasal
irrig
devic
spacer
may
clean
tap
well
distil
bottl
water
follow
nebul
maintain
use
either
hot
cold
method
figur
incorpor
machin
specif
instruct
outlin
respiratori
equip
humidifi
reservoir
need
clean
use
steril
avoid
acquisit
soilborn
organ
burkholderia
spp
typic
cf
pathogen
aspergillu
spp
cf
foundat
recommend
minim
exposur
activ
gener
dust
organ
hot
tub
stagnant
water
avoid
p
aeruginosa
often
harbor
children
cf
age
birth
year
initi
infect
methicillin
sensit
aureu
mssa
follow
haemophilu
influenza
peak
schoolag
children
p
aeruginosa
presenc
p
aeruginosa
rise
steadili
adolesc
becom
promin
organ
infect
cf
airway
adulthood
import
organ
adult
includ
mssa
mrsa
multidrug
resist
pseudomona
gram
neg
rod
burkholderia
cepacia
complex
shown
figur
primari
antimicrobi
chemoprophylaxi
mssa
controversi
within
cf
commun
commonli
practic
europ
children
age
diagnosi
year
may
given
daili
flucloxacillin
recommend
unit
kingdom
uk
base
cf
publish
literatur
show
cf
children
fewer
isol
mssa
less
cough
reduc
hospit
narrow
spectrum
antistaphylococc
antibiot
flucloxacillin
start
earli
infanc
continu
year
practic
result
lung
function
studi
use
prophylact
cephalexin
result
increas
risk
p
aeruginosa
cochran
review
note
trend
toward
increas
p
aeruginosa
isol
children
age
year
treat
due
concern
regard
acceler
p
aeruginosa
acquisit
american
pediatr
pulmonologist
remain
retic
implement
practic
current
cf
foundat
recommend
better
defin
longterm
flucloxacillin
treatment
infant
cf
ongo
uk
studi
cystic
fibrosi
cf
antistaphylococc
antibiot
prophylaxi
trial
cf
start
random
registri
trial
assess
safeti
efficaci
flucloxacillin
longterm
prophylaxi
agent
http
organ
pathogen
refer
abil
increas
pex
frequenc
diminish
lung
function
increas
bacteria
increas
airway
inflamm
rational
erad
diminish
longterm
pulmonari
consequ
associ
ongo
inflamm
prevent
chronic
uk
cf
trust
european
cystic
fibrosi
societi
ecf
recommend
erad
p
aeruginosa
mssa
mrsa
h
wherea
cf
foundat
specif
erad
recommend
p
due
devast
effect
lung
function
rel
contraind
lung
transplant
regimen
elimin
b
cepacia
complex
current
studi
report
success
begin
appear
pseudomona
aeruginosa
erad
p
aeruginosa
cfrb
may
accomplish
inhal
tobramycin
solut
dri
altern
inhal
aztreonam
lysin
may
use
specif
discuss
recent
cf
foundat
guidelin
foundat
note
data
support
inhal
aztreonam
yet
releas
recommend
made
europ
strongli
recommend
cf
trust
patient
often
start
inhal
colistin
oral
methicillin
sensit
staphylococcu
mssacultureposit
cf
patient
cf
trust
escf
recommend
oral
therapi
week
alreadi
primari
chemoprophylaxi
flucloxacillin
dose
flucloxacillin
increas
second
antistaphylococc
antibiot
ad
erad
daili
prophylaxi
week
treatment
everi
time
patient
cultur
posit
may
continu
altern
cf
trust
suggest
regardless
precultur
therapi
patient
continu
secondari
chemoprophylaxi
durat
secondari
chemoprophylaxi
unclear
detail
reader
refer
cf
trust
antibiot
treatment
cystic
fibrosi
erad
specif
review
cf
foundat
patient
becom
chronic
infect
mssa
foundat
state
insuffici
evid
support
recommend
secondari
haemophilu
erad
h
influenza
uk
cf
trust
escf
recommend
h
influenza
direct
oral
therapi
h
influenza
persist
sputa
antibiot
therapi
continu
clinician
may
consid
continu
suppress
antibiot
done
mssa
cf
foundat
current
recommend
regard
erad
secondari
prophylaxi
h
influenza
methicillin
resist
staphylococcu
aureu
global
consensu
regard
effect
mrsa
erad
protocol
erad
recommend
uk
cf
trust
effect
differ
protocol
acut
chronic
infect
activ
uk
cf
trust
suggest
patient
given
rifampicin
fusid
acid
without
inhal
vancomycin
littl
data
support
northern
ireland
region
adult
cystic
fibrosi
center
belfast
publish
retrospect
review
patient
newli
acquir
mrsa
major
patient
treat
use
cf
trust
oral
regimen
ie
without
inhal
vancomycin
ad
nasal
mupirocin
chlorhexidin
bodi
wash
day
result
success
rate
unexpectedli
complic
known
fusid
acid
gastrointestin
distress
mani
us
john
hopkin
univers
recent
publish
result
phase
ii
trial
chronic
mrsa
pulmonari
infect
evalu
combin
oral
therapi
rifampin
combin
either
trimethoprimsulfamethoxazol
doxycyclin
skin
treatment
mupirocin
nasal
cream
chlorhexidin
bodi
wash
without
inhal
vancomycin
find
signific
differ
sputum
cultur
month
receiv
inhal
vancomycin
receiv
tast
match
addit
starttoo
studi
team
activ
recruit
patient
openlabel
phase
ii
studi
examin
effect
oral
antibiot
trimethoprimsulfamethoxazol
minocyclin
intranas
mupirocin
chlorhexidin
gargl
microbiota
patient
newli
acquir
mrsa
pulmonari
infect
chronic
pulmonari
therapi
daili
multipl
time
daili
medic
regimen
aim
improv
clinic
outcom
improv
patient
mucociliari
clearanc
multifacet
approach
util
airway
clearanc
techniqu
act
combin
inhal
osmot
mucolyt
aerosol
antimicrobi
agent
antiinflammatori
varieti
act
util
cfrb
ncfrb
purpos
loosen
viscou
mucou
airway
wall
util
mechan
forc
includ
cpt
without
posit
drainag
huff
cough
posit
end
expiratori
pressur
without
oscil
autogen
drainag
high
frequenc
chest
oscil
method
improv
patient
symptom
qol
score
none
yet
shown
superior
anoth
either
diseas
maneuv
typic
use
simultan
nebul
medic
detail
inform
regard
current
studi
recommend
reader
refer
wilson
lm
colleaguescochran
review
flume
pa
colleaguesrespiratori
care
lee
al
colleaguescochran
review
recommend
aerosol
osmot
mucolyt
agent
often
base
diseas
sever
defin
percent
predict
forc
expiratori
volum
normal
greater
mildli
impair
predict
moder
impair
predict
sever
impair
function
improv
qualiti
airway
surfac
liquid
asl
addit
agent
may
caus
bronchospasm
one
consid
toler
test
prior
initi
therapi
pretreat
use
short
act
lung
defend
inhal
pathogen
primarili
via
mucociliari
clearanc
vital
part
healthi
asl
asl
well
studi
cf
base
gel
mucou
model
asl
compris
two
layer
perimembran
aqueou
layer
term
periciliari
liquid
pcl
lie
mucou
layer
intend
entrap
inhal
ideal
pcl
height
extend
cilium
approxim
allow
cilia
beat
unimped
thin
liquid
layer
cilia
propel
thicker
mucou
layer
caudal
separ
mucin
rich
cfrb
layer
lose
volum
thu
height
due
dehydr
result
viscou
mucou
plaqu
plug
contain
neutrophil
entrap
microorgan
particul
aerosol
osmot
agent
also
known
hydrat
intend
thin
asl
hyperton
salin
ht
dri
powder
mannitol
studi
purpos
inhal
hyperton
salin
result
sustain
increas
mucou
clearanc
small
absolut
differ
lung
function
mild
improv
qol
reduct
pex
patient
thu
recommend
use
cf
patient
older
year
cf
foundat
part
ecf
best
practic
dri
powder
mannitol
use
europ
time
recommend
ecf
increas
may
reduc
number
pex
patient
moder
impair
lung
may
us
feder
drug
administr
approv
use
improv
lung
function
cf
adult
base
result
long
term
administr
inhal
mannitol
cystic
fibrosi
safeti
efficaci
trial
adult
cystic
fibrosi
subject
doubleblind
random
parallel
multicent
studi
random
cf
adult
receiv
either
inhal
mannitol
mg
twice
daili
placebo
twice
daili
week
patient
studi
arm
signific
increas
compar
placebo
group
howev
similar
number
pex
advers
event
extracellular
dna
releas
leukocyt
constitut
approxim
dri
weight
cf
airway
recombin
human
dnase
rhdnase
also
known
dornasealpha
hydrolyz
dna
decreas
viscos
asl
patient
cf
chronic
use
least
week
rhdnase
shown
improv
qol
patient
moderatetosever
lung
diseas
well
reduc
pex
frequenc
increas
patient
mild
sever
lung
result
sustain
discontinu
thu
cf
foundat
ecf
recommend
longterm
anoth
mucolyt
agent
nacetylcystein
trial
found
benefici
effect
pulmonari
function
treatment
inhal
antibiot
recommend
patient
cfrb
chronic
infect
p
cf
patient
chronic
pseudomon
infect
prescrib
cycl
onoff
regimen
inhal
antibiot
therapi
tobramycin
twice
daili
solut
dri
powder
aerosol
aztreonam
three
time
daili
may
inhal
colistin
solut
dri
powder
recommend
ecf
cf
trust
use
yet
recommend
cf
cf
patient
chronic
infect
p
aeruginosa
inhal
tobramycin
enter
macrolid
therapi
reduc
exacerb
frequenc
loss
azithromycin
trial
publish
journal
american
medic
associ
jama
includ
balanc
number
patient
chronic
inhal
tobramycin
intervent
control
group
suggest
azithromycin
ad
benefit
inhal
use
recommend
cf
foundat
cf
trust
past
sever
year
howev
new
data
suggest
concomit
use
inhal
tobramycin
oral
azithromycin
may
antagonist
effect
nichol
colleagu
publish
journal
cystic
fibrosi
chang
decreas
qol
tobramycin
azithromycin
use
togeth
addit
greater
decreas
bacteri
burden
p
aeruginosa
inhal
tobramycin
use
alon
versu
combin
interestingli
increas
qol
patient
use
azithromycin
inhal
studi
relationship
inhal
tobramycin
enter
azithromycin
seattl
children
hospit
sponsor
phase
iv
prospect
random
doubleblind
placebocontrol
trial
addit
thrice
weekli
azithromycin
mg
chronic
inhal
tobramycin
adolesc
adult
cf
time
cf
foundat
recommend
chronic
suppress
inhal
antibiot
organ
due
pauciti
data
current
howev
savara
pharmaceut
conduct
phase
iii
doubl
blind
multicent
random
placebo
control
parallelgroup
studi
analyz
mean
absolut
chang
patient
given
mg
inhal
vancomycin
powder
twice
daili
although
tradit
use
antimicrobi
azithromycin
use
antiinflammatori
agent
cfrb
continu
azithromycin
initi
recommend
chronic
infect
p
aeruginosa
remain
cf
past
sever
year
accumul
data
suggest
patient
chronic
infect
pseudomona
may
also
benefit
ongo
macrolid
therapi
cochran
review
includ
cf
patient
regardless
pseudomon
statu
found
azithromycin
reduc
frequenc
pulmonari
exacerb
improv
lung
function
author
mention
although
pseudomon
statu
unlik
confound
factor
regard
pulmonari
function
studi
infect
organ
current
cf
foundat
cf
trust
suggest
consider
macrolid
therapi
chronic
infect
regardless
popul
azithromycin
use
patient
must
screen
ntm
infect
prior
begin
therapi
throughout
cours
one
monitor
sideeffect
qt
prolong
ototox
inhal
corticosteroid
recommend
chronic
medic
indic
use
patient
concomit
asthma
chronic
obstruct
pulmonari
use
hmg
coa
reductas
inhibitor
yet
adequ
studi
cf
popul
ibuprofen
studi
cfrb
efficaci
pediatr
popul
insuffici
data
recommend
use
final
leukotrien
modifi
requir
studi
recommend
chronic
use
role
thorac
surgeri
patient
cfrb
typic
reserv
recurr
refractori
infect
hemoptysi
isol
given
lobe
lobar
segment
refractori
surgeri
undertaken
follow
discuss
rel
merit
intend
oper
patient
qol
without
oper
futur
need
lung
transplant
surgeri
perform
infrequ
avail
data
often
weaken
retrospect
design
small
sampl
size
avail
analys
howev
report
mix
conclus
often
due
differ
patient
age
sever
lung
diseas
measur
cohort
pediatr
patient
age
year
marmon
colleagu
report
improv
symptomatolog
fewer
subsequ
hospit
need
postop
popul
predomin
two
report
death
preoper
rang
smith
colleagu
report
similar
clinic
function
experi
patient
age
year
howev
note
patient
poor
outcom
find
corrobor
sheikh
colleagu
popul
patient
median
age
year
patient
mani
individu
three
group
also
experienc
postop
declin
furthermor
although
longterm
mortal
affect
patient
transplant
indic
histori
prior
cardiothorac
surgeri
ct
lower
posttranspl
peak
higher
rate
respiratori
renal
complic
increas
postop
bleed
compar
without
prior
thu
remain
precari
balanc
patient
current
possibl
futur
treatment
interestingli
despit
similar
patient
sign
symptom
microbiota
cfrb
ncfrb
differ
true
preval
specif
organ
infect
ncfrb
airway
difficult
describ
pauciti
pool
data
cultur
data
report
differ
studi
recent
publish
us
bronchiectasi
registri
report
reveal
wide
distribut
sever
promin
organ
p
aeruginosa
commun
acquir
organ
h
influenza
moraxella
catarrhali
anaerob
organ
tabl
note
ntm
common
bronchiectasi
registri
report
may
secondari
registr
bia
larg
ntm
treatment
center
activ
enrol
specif
recommend
primari
chemoprophylaxi
patient
ncfrb
unlik
cfrb
recommend
bacteri
erad
ncfrb
publish
p
aeruginosa
lack
data
evalu
regimen
pleas
note
recommend
regimen
differ
ncfrb
cfrb
base
clinic
common
practic
european
respiratori
societi
publish
three
differ
pathway
number
erad
may
attempt
step
within
pathway
separ
sputum
cultur
escal
treatment
patient
remain
cultur
specif
asl
well
examin
ncfrb
cfrb
also
limit
strength
evid
support
osmot
mucolyt
therapi
set
ncfrb
dearth
data
pauciti
subject
avail
studi
nevertheless
evid
ht
result
improv
qol
score
european
respiratori
societi
er
guidelin
recommend
use
use
inhal
mannitol
clear
popul
although
inhal
mannitol
increas
sputum
weight
time
first
pex
decreas
frequenc
also
phase
iii
trial
exclud
patient
posit
mannitol
provoc
test
patient
still
experienc
bronchospasm
studi
arm
wherea
report
bronchospasm
placebo
final
studi
util
inhal
mannitol
ht
result
improv
none
therapi
shown
decreas
rate
symptomat
similar
cfrb
ncfrb
led
assumpt
ncfrb
parallel
diseas
respond
similarli
therapi
proven
effect
cfrb
supposit
proven
danger
use
rhdnase
ncfrb
patient
deleteri
associ
increas
treatment
inhal
antibiot
recommend
patient
ncfrb
experienc
three
exacerb
preced
year
regardless
pulmonari
may
treat
inhal
antibiot
macrolid
chronic
infect
p
aeruginosa
begin
daili
nebul
antibiot
data
yet
support
monthli
cycl
recommend
base
primarili
two
random
placebocontrol
studi
demonstr
improv
clinic
outcom
prescrib
suppress
inhal
antimicrobi
therapi
note
inhal
aztreonam
recommend
due
decreas
qol
score
increas
macrolid
recommend
replac
ad
lack
respons
intoler
inhal
antimicrobi
individu
chronic
infect
p
aeruginosa
start
macrolid
therapi
base
result
three
promin
random
doubleblind
placebocontrol
studi
embrac
bat
embrac
bat
report
reduct
frequenc
pex
bless
similar
result
manifest
p
aeruginosa
infect
despit
find
bless
macrolid
therapi
suggest
first
choic
frequent
exacerb
without
chronic
p
aeruginosa
infect
popul
er
suggest
although
poor
support
evid
patient
continu
exacerb
macrolid
intoler
one
may
prescrib
longterm
target
inhal
therapi
clinic
declin
occur
patient
may
subsequ
place
target
oral
import
rememb
prior
initi
macrolid
therapi
coinfect
ntm
must
addit
continu
screen
ntm
ought
perform
throughout
therapi
along
regular
monitor
drug
toxic
qt
prolong
ototox
cfrb
inhal
corticosteroid
indic
patient
diagnos
concomit
asthma
chronic
obstruct
pulmonari
hmg
coa
reductas
inhibitor
yet
found
effect
patient
ibuprofen
yet
studi
ncfrb
thu
recommend
regard
also
cfrb
leukotrien
modifi
requir
studi
recommend
chronic
surgic
indic
ncfrb
broader
cfrb
similarli
cf
treatment
local
refractori
infect
uncontrol
hemoptysi
refractori
infect
popul
often
due
mani
patient
howev
often
experi
significantli
diminish
qol
even
approach
thu
contrast
cf
diminish
qol
may
prompt
surgic
addit
mani
case
ncfrb
due
local
structur
chang
right
middl
lobe
syndrom
postinfecti
bronchiectasi
prior
tuberculosi
resect
may
result
symptom
resolut
zhang
colleagu
retrospect
review
outcom
patient
underw
resect
local
diseas
signific
hemoptysi
pulmonari
abscess
empyema
chronic
product
cough
chronic
infect
refractori
antimicrobi
report
symptom
resolut
improv
chang
declin
patient
result
emphas
meticul
patient
select
paramount
success
outcom
age
year
renal
failur
creatinin
clearanc
mlmin
associ
increas
postop
mortal
addit
preoper
associ
increas
risk
postop
thu
follow
care
patient
select
surgic
consider
may
occur
commonli
infect
control
prevent
paramount
care
patient
cfrb
ncfrb
complex
endeavor
combin
educ
protocol
develop
environment
chang
behavior
chang
adher
treatment
plan
combin
decreas
bacteri
transmiss
temper
pulmonari
consequ
bacteri
infect
detail
attent
team
individu
commit
implement
prevent
delay
acquisit
mani
patholog
organ
control
effect
chronic
infect
offer
patient
decreas
mortal
fewer
exacerb
importantli
improv
qol
